JP2016510787A - クリゾチニブを含む剤形 - Google Patents

クリゾチニブを含む剤形 Download PDF

Info

Publication number
JP2016510787A
JP2016510787A JP2015562144A JP2015562144A JP2016510787A JP 2016510787 A JP2016510787 A JP 2016510787A JP 2015562144 A JP2015562144 A JP 2015562144A JP 2015562144 A JP2015562144 A JP 2015562144A JP 2016510787 A JP2016510787 A JP 2016510787A
Authority
JP
Japan
Prior art keywords
crizotinib
lubricant
tablet
tablets
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015562144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510787A5 (enExample
Inventor
ステファン，ラルフ
プロフル，ザビーネ
Original Assignee
ラシオファルム ゲーエムベーハー
ラシオファルム ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラシオファルム ゲーエムベーハー, ラシオファルム ゲーエムベーハー filed Critical ラシオファルム ゲーエムベーハー
Publication of JP2016510787A publication Critical patent/JP2016510787A/ja
Publication of JP2016510787A5 publication Critical patent/JP2016510787A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015562144A 2013-03-13 2014-03-13 クリゾチニブを含む剤形 Pending JP2016510787A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361780015P 2013-03-13 2013-03-13
US61/780,015 2013-03-13
EP13001257 2013-03-13
EP13001257.8 2013-03-13
PCT/EP2014/054933 WO2014140159A1 (en) 2013-03-13 2014-03-13 Dosage form comprising crizotinib

Publications (2)

Publication Number Publication Date
JP2016510787A true JP2016510787A (ja) 2016-04-11
JP2016510787A5 JP2016510787A5 (enExample) 2017-04-13

Family

ID=47900469

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015562144A Pending JP2016510787A (ja) 2013-03-13 2014-03-13 クリゾチニブを含む剤形

Country Status (5)

Country Link
US (1) US20160022661A1 (enExample)
EP (1) EP2968167A1 (enExample)
JP (1) JP2016510787A (enExample)
EA (1) EA201591644A1 (enExample)
WO (1) WO2014140159A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108721243B (zh) * 2017-04-25 2022-07-08 正大天晴药业集团股份有限公司 克唑替尼药物组合物及其制备方法
AU2020417043A1 (en) * 2019-12-31 2022-06-09 Pfizer Inc. Stable immediate release tablet and capsule formulations of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10511112A (ja) * 1995-09-15 1998-10-27 ファイザー・インコーポレーテッド ダリフェナシン含有製剤
JP2007153894A (ja) * 2005-12-05 2007-06-21 Pfizer Prod Inc 異常細胞成長の処置方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009015702A1 (de) * 2009-03-31 2010-10-07 Ratiopharm Gmbh Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10511112A (ja) * 1995-09-15 1998-10-27 ファイザー・インコーポレーテッド ダリフェナシン含有製剤
JP2007153894A (ja) * 2005-12-05 2007-06-21 Pfizer Prod Inc 異常細胞成長の処置方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 11, no. 6, JPN6017041534, 2001, pages 981 - 986, ISSN: 0003672500 *
薬剤学, vol. 71, no. 4, JPN6017041533, 2011, pages 223 - 227, ISSN: 0003672499 *

Also Published As

Publication number Publication date
US20160022661A1 (en) 2016-01-28
WO2014140159A1 (en) 2014-09-18
EA201591644A1 (ru) 2016-05-31
EP2968167A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
EP2854759B1 (en) Dosage forms comprising apixaban and matrix former
JP5289975B2 (ja) マンニトール又は乳糖を含有する固形製剤
JP6679495B2 (ja) 免疫抑制製剤
KR20130041144A (ko) 데페라시록스의 경구투여용 제제
EP2099432B1 (en) Method of forming a tablet comprising pre-blend of ibuprofen and silicon dioxide
JP2012503613A (ja) コンパクト化シナカルセット
JP6019116B2 (ja) （トリメトキシフェニルアミノ）ピリミジニル製剤
JP2019142834A (ja) プレガバリン並びに好適な賦形剤を含有する固形製剤
CA2920758A1 (en) Pharmaceutical compositions of fingolimod
WO2012100948A1 (en) Pharmaceutical compositions comprising tasocitinib
EP3860606A1 (en) Pharmaceutical composition comprising lenvatinib esylate or tosylate
TWI721946B (zh) 色瑞替尼調配物
US20120058183A1 (en) Retigabine tablets, preferably having modified release
JP2016510787A (ja) クリゾチニブを含む剤形
WO2009043914A1 (en) Multi particulate matrix system containing galantamine
WO2016042493A1 (en) Pharmaceutical compositions of fingolimod
JP2020176090A (ja) ダサチニブ無水物を含有する固形製剤の製造方法
JP2022103591A (ja) 時限放出型顆粒およびその用途
US20160081971A1 (en) Method for producing dosage form comprising odanacatib
EP3731823A1 (en) A pharmaceutical formulation for oral administration comprising dabigatran etexilate
WO2017114597A1 (en) Pharmaceutical dosage forms comprising ((cis)-n-(4-(dimethylamino)-1,4- diphenylcyclohexyl)-n-methylcinnamamide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171031

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180529